The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
EMA approval of lenalidomide plus rituximab for adult patients with R/R FL
The Lymphoma Hub has recently covered news on the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, issuing a positive opinion for the approval of lenalidomide plus rituximab (R2) as a treatment for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). You can read it here.
On the 20th of December 2019, the R2 combination was approved by the EMA, based on the positive data from multi-center phase III studies AUGMENT (NCT01938001) and MAGNIFY (NCT01996865).1
You can read the Lymphoma Hub’s coverage of the AUGMENT study, watch an interview with Marek Trněný discussing the post-hoc analysis of the data in the elderly population, and Mathias Rummel discussing the MAGNIFY trial.
References